Shares of Hologic (HOLX) jumped to a 52-week high early Wednesday for the medical imaging company after a new study supported its 3D mammography technology. An interim analysis of 12,631 mammograms found that those using a combination of 3D and 2D had a 27% better detection rate and a 15% lower false-positive rate than those using 2D alone. Hologic sells a 3D system called Selenia, and the new study should help it in reimbursement negotiations